{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,10,28]],"date-time":"2023-10-28T14:48:14Z","timestamp":1698504494111},"reference-count":40,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2001,12,25]],"date-time":"2001-12-25T00:00:00Z","timestamp":1009238400000},"content-version":"vor","delay-in-days":1211,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Helicobacter"],"published-print":{"date-parts":[[1998,9]]},"abstract":"<jats:sec><jats:title>Background.<\/jats:title><jats:p>The combination of ranitidine bismuth citrate (RBC) and clarithromycin (CLR) was compared with each treatment alone for the eradication of <jats:italic>H. pylori<\/jats:italic> and healing of duodenal ulcers in patients infected with <jats:italic>H. pylori.<\/jats:italic><\/jats:p><\/jats:sec><jats:sec><jats:title>Methods.<\/jats:title><jats:p>This two\u2010phase, randomized, double\u2010blind, placebo\u2010controlled, multicenter study evaluated 203 patients with an active duodenal ulcer treated with either (1) RBC 400 mg BID for 4 weeks plus CLR 500 mg TID for the first 2 weeks; (2) RBC 400 mg BID for 4 weeks plus placebo TID for the first 2 weeks; (3) placebo BID for 4 weeks plus CLR 500 mg TID for the first 2 weeks; or (4) placebo BID for 4 weeks plus placebo TID for the first 2 weeks. Patients with healed ulcers after treatment entered a 24\u2010week observation phase for the assessment of <jats:italic>H. pylori<\/jats:italic> and ulcer relapse.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results.<\/jats:title><jats:p>Four\u2010week ulcer healing rates were higher with RBC + CLR (71%) and RBC alone (66%) compared with placebo (15%;<jats:italic>p<\/jats:italic> &lt; 0.05) and CLR alone (49%). <jats:italic>H. pylori<\/jats:italic> eradication rates were significantly higher with RBC + CLR (86%) compared with RBC alone (0%, <jats:italic>p<\/jats:italic> &lt; .001) or CLR alone (24%, <jats:italic>p<\/jats:italic> &lt; .001). Ulcer recurrence rates after 6 months were lower in patients eradicated of <jats:italic>H. pylori<\/jats:italic> infection (17%) compared with patients who remained infected (43%). All treatments were well tolerated.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions.<\/jats:title><jats:p>Ranitidine bismuth citrate plus clarithromycin is a simple, convenient, and well\u2010tolerated dual therapy regimen that is effective in eradicating <jats:italic>H. pylori<\/jats:italic> and healing duodenal ulcers in patients infected with <jats:italic>H. pylori.<\/jats:italic> The eradication of <jats:italic>H. pylori<\/jats:italic> in patients with healed ulcers significantly reduces the rate of ulcer relapse.<\/jats:p><\/jats:sec>","DOI":"10.1046\/j.1523-5378.1998.08050.x","type":"journal-article","created":{"date-parts":[[2003,3,11]],"date-time":"2003-03-11T23:20:56Z","timestamp":1047424856000},"page":"212-221","source":"Crossref","is-referenced-by-count":9,"title":["Ranitidine Bismuth Citrate Plus Clarithromycin: A Dual Therapy Regimen for Patients with Duodenal Ulcer"],"prefix":"10.1111","volume":"3","author":[{"given":"Frank L.","family":"Lanza","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stephen J.","family":"Sontag","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Arthur A.","family":"Ciociola","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Deborah L.","family":"Sykes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amy","family":"Heath","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David J.","family":"McSorley","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2001,12,25]]},"reference":[{"key":"e_1_2_6_2_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF01296437"},{"key":"e_1_2_6_3_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199302043280512"},{"key":"e_1_2_6_4_2","unstructured":"Helicobacter pylori: causal agent in peptic ulcer disease? Working Party Reports of the World Congresses in Gastroenterology 1990; 36\u2013\u200345."},{"key":"e_1_2_6_5_2","first-page":"59","article-title":"The prevalence of H. pylori in peptic ulcer disease","volume":"9","author":"Kuipers EJ","year":"1995","journal-title":"Aliment Pharmacol Ther"},{"key":"e_1_2_6_6_2","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-116-9-705"},{"key":"e_1_2_6_7_2","first-page":"24","article-title":"Helicobacter pylori and duodenal ulcer recurrence","volume":"87","author":"Patchett S","year":"1992","journal-title":"Am J Gastroenterol"},{"key":"e_1_2_6_8_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199302043280503"},{"key":"e_1_2_6_9_2","doi-asserted-by":"crossref","unstructured":"Helicobacter pyloriin peptic ulcer disease\u2013NIH Consensus Conference. JAMA 1994; 272:65\u20139.","DOI":"10.1001\/jama.272.1.65"},{"key":"e_1_2_6_10_2","doi-asserted-by":"publisher","DOI":"10.1136\/gut.31.9.999"},{"key":"e_1_2_6_11_2","first-page":"1993","article-title":"Randomized study comparing one with two weeks of quadruple therapy for eradicating Helicobacter pylori.","volume":"89","author":"DeBoer WA","year":"1994","journal-title":"Am J Gastroenterol"},{"key":"e_1_2_6_12_2","first-page":"1072","article-title":"Choosing the best anti\u2010Helicobacter pylori therapy: effect of antimicrobial resistance","volume":"91","author":"Graham DY","year":"1996","journal-title":"Am J Gastroenterol"},{"key":"e_1_2_6_13_2","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.1982.192"},{"key":"e_1_2_6_14_2","doi-asserted-by":"publisher","DOI":"10.1136\/gut.24.10.904"},{"key":"e_1_2_6_15_2","first-page":"1359","article-title":"Nocturnal administration of five antihistamine H2 receptor antagonists: a single\u2010blind comparative study on acid secretion in man (abstract)","volume":"88","author":"Dammann HG","year":"1985","journal-title":"Gastroenterology"},{"key":"e_1_2_6_16_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(88)90929-4"},{"key":"e_1_2_6_17_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(87)91545-5"},{"key":"e_1_2_6_18_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199104113241507"},{"key":"e_1_2_6_19_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199003293221307"},{"key":"e_1_2_6_20_2","doi-asserted-by":"publisher","DOI":"10.1097\/00004836-198806000-00003"},{"issue":"4","key":"e_1_2_6_21_2","first-page":"A114","article-title":"The efficacy of ranitidine bismuth citrate (GR 122311X) in the treatment of Helicobacter pylori infection (abstract)","volume":"102","author":"Logan RPH","year":"1992","journal-title":"Gastroenterology"},{"key":"e_1_2_6_22_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2036.1993.tb00127.x"},{"key":"e_1_2_6_23_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2036.1996.46188000.x"},{"key":"e_1_2_6_24_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2036.1995.tb00412.x"},{"issue":"4","key":"e_1_2_6_25_2","first-page":"A50","article-title":"Safety and pharmacokinetics of chronic oral dosing of GR122311X (ranitidine bismuth citrate), a new bismuth compound with anti\u2010secretory activity (abstract)","volume":"102","author":"Ciociola AA","year":"1992","journal-title":"Gastroenterology"},{"issue":"4","key":"e_1_2_6_26_2","first-page":"A51","article-title":"Safety and pharmacokinetics of ascending oral doses of GR122311X (ranitidine bismuth citrate), a new bismuth compound with anti\u2010secretory properties (abstract)","volume":"102","author":"Ciociola AA","year":"1992","journal-title":"Gastroenterology"},{"issue":"1","key":"e_1_2_6_27_2","first-page":"A62","article-title":"GR122311X can significantly reduce the emergence of H. pylori strains resistant to antibiotics (abstract)","volume":"73","author":"McLaren A","year":"1995","journal-title":"Gut"},{"issue":"6","key":"e_1_2_6_28_2","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1128\/jcm.22.6.1007-1010.1985","article-title":"Characterization of \u201cCampylobacter pyloridis\u201d by culture, enzymatic profile, and protein content","volume":"22","author":"Megraud F","year":"1985","journal-title":"J Clin Microbiol"},{"key":"e_1_2_6_29_2","doi-asserted-by":"publisher","DOI":"10.1016\/0046-8177(94)90191-0"},{"key":"e_1_2_6_30_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.0953-0673.1996.00251.x"},{"issue":"1","key":"e_1_2_6_31_2","first-page":"T131","article-title":"Ranitidine bismuth citrate in combination with clarithromycin either 250mg qds or 500mg bd eradicates Helicobacter pylori in up to 96% of patients with active duodenal ulcer disease (abstract)","volume":"39","author":"Lancaster Smith MJ","year":"1996","journal-title":"Gut"},{"key":"e_1_2_6_32_2","first-page":"166","article-title":"GR122311X (ranitidine bismuth citrate) for the eradication of Helicobacter pylori (abstract)","volume":"37","author":"Pounder RE","year":"1995","journal-title":"Gut"},{"key":"e_1_2_6_33_2","doi-asserted-by":"publisher","DOI":"10.1016\/0016-5085(95)22875-6"},{"key":"e_1_2_6_34_2","first-page":"1382","article-title":"The synergistic interaction between GR122311X and clarithromycin against Helicobacter (abstract)","volume":"89","author":"McLaren A","year":"1994","journal-title":"Am J Gastroenterol"},{"key":"e_1_2_6_35_2","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-115-4-266"},{"issue":"1","key":"e_1_2_6_36_2","first-page":"A42","article-title":"GR122311X (ranitidine bismuth citrate) with clarithromycin for the eradication of Helicobacter pylori (abstract)","volume":"37","author":"Pounder RE","year":"1995","journal-title":"Gut"},{"key":"e_1_2_6_37_2","doi-asserted-by":"publisher","DOI":"10.3109\/00365529309098341"},{"key":"e_1_2_6_38_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2036.1992.tb00556.x"},{"key":"e_1_2_6_39_2","doi-asserted-by":"publisher","DOI":"10.1016\/0140-6736(90)91301-P"},{"key":"e_1_2_6_40_2","doi-asserted-by":"publisher","DOI":"10.1016\/0016-5085(92)90095-G"},{"key":"e_1_2_6_41_2","first-page":"505","article-title":"Patient factors affecting Helicobacter pylori eradication with triple therapy","volume":"88","author":"Cutler AF","year":"1993","journal-title":"Am J Gastroenterol"}],"container-title":["Helicobacter"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1046%2Fj.1523-5378.1998.08050.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1046\/j.1523-5378.1998.08050.x","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1046\/j.1523-5378.1998.08050.x","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1046\/j.1523-5378.1998.08050.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,11]],"date-time":"2023-09-11T05:30:05Z","timestamp":1694410205000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1046\/j.1523-5378.1998.08050.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1998,9]]},"references-count":40,"journal-issue":{"issue":"3","published-print":{"date-parts":[[1998,9]]}},"alternative-id":["10.1046\/j.1523-5378.1998.08050.x"],"URL":"https:\/\/doi.org\/10.1046\/j.1523-5378.1998.08050.x","archive":["Portico"],"relation":{},"ISSN":["1083-4389","1523-5378"],"issn-type":[{"value":"1083-4389","type":"print"},{"value":"1523-5378","type":"electronic"}],"subject":[],"published":{"date-parts":[[1998,9]]}}}